Page 104 - 88_01

rofecoxib and myocardial infarction in perimenopausal women. J
Cardiovasc Pharmacol. 2011;57(2):194–200.
105. Wernli KJ, Hampton JM, Trentham-Dietz A, Newcomb PA. Use
of antidepressants and NSAIDs in relation to mortality in long-
term breast cancer survivors. Pharmacoepidemiol Drug Saf.
2011;20(2):131–7.
106. Wu L-C, Leong P-Y, Yeo K-J, Li T-Y, Wang Y-H, Chiou J-Y, et
al. Celecoxib and sulfasalazine had negative association with
coronary artery diseases in patients with ankylosing spondylitis:
A nation-wide, population-based case-control study. Medicine.
2016;95(36):e4792.
107. Chang C-H, Lin J-W, Chen H-C, Kuo C-W, Shau W-Y, Lai M-S. Non-
steroidal anti- inflammatory drugs and risk of lower gastrointestinal
adverse events: a nationwide study in Taiwan. Gut.
2011;60(10):1372–8.
108. Abraham NS, Hartman C, Castillo D, Richardson P, Smalley W. Ef-
fectiveness of national provider prescription of PPI gastropro-
tection among elderly NSAID users. Am J Gastroenterol.
2008;103(2):323–32.
109. Chang C-H, Chen H-C, Lin J-W, Kuo C-W, Shau W-Y, Lai M-S. Risk
of hospitalization for upper gastrointestinal adverse events associa-
ted with nonsteroidal anti-inflammatory drugs: a nationwide case-
crossover study in Taiwan. Pharmacoepidemiol Drug Saf.
2011;20:763–71.
110. Castellsague J, Pisa F, Rosolen V, Drigo D, Riera-Guardia N, Gian-
grego M, et al.. Risk of upper gastrointestinal complications in a co-
hort of users of nimesulide and other nonsteroidal anti-inflammatory
drugs in Friuli Venezia Giulia, Italy. Pharmacoepidemiol Drug
Saf. 2013;22:365–75.
111. Castellsague J, Holick CN, Hoffman CC, Gimeno V, Stang MR, Perez-
Gutthann S. Risk of upper gastrointestinal complications associated
with cyclooxygenase-2 selective and nonselective nonsteroidal an-
tiinflammatory drugs. Pharmacotherapy. 2009;29(12):1397–407.
112. Battistella M, Mamdani M, Juurlink DN, Rabeneck L, Laupacis
A. Risk of Upper 2 Inhibitors. Arch Intern Med. 2005;165:189–
92.
113. Crooks CJ, West J, Card TR. Comorbidities affect risk of nonvariceal
upper gastrointestinal bleeding. Gastroenterology.
2013;144(7):1384–93.
114. Etminan M, LÉvesque L, Fitzgerald JM, Brophy JM. Risk of upper
gastrointestinal bleeding with oral bisphosphonates and non ste-
roidal anti-inflammatory drugs: A case-control study. Aliment Phar-
macol Ther. 2009;29(11):1188–92.
115. García Rodríguez LA, Barreales Tolosa L. Risk of Upper Gastrointestinal
Complications Among Users of Traditional NSAIDs and CO-
XIBs in the General Population. Gastroenterology.
2007;132(2):498–506.
102 Analysis and evaluation of cardiovascular and gastrointestinal risk of nonsteroidal
anti-inflammatory drugs selective and non-selective cyclooxygenase inhibitors
Antonio Margo
An. Real Acad. Farm.Vol. 88. nº 1 (2022) · pp. 85-103
ANALES
RANF
www.analesranf.com
116. García Rodríguez LA, Lin KJ, Hernández-Díaz S, Johansson S. Risk
of upper gastrointestinal bleeding with low-dose acetylsalicylic acid
alone and in combination with clopidogrel and other medications.
Circulation. 2011;123(10):1108–15.
117. Helin-Salmivaara A, Saarelainen S, Grönroos JM, Vesalainen R,
Klaukka T, Huupponen R. Risk of upper gastrointestinal events with
the use of various NSAIDs: A case-control study in a general popu-
lation. Scand J Gastroenterol. 2007;42:923–32.
118. Hippisley-cox J, Coupland C, Logan R. Risk of adverse gastrointestinal
outcomes in patients taking cyclo-oxygenase-2 inhibitors or con-
ventional non-steroidal anti-inflammatory drugs: population based
nested case-control analysis. BMJ. 2005;331:1310–6.
119. Humes DJ, Fleming KM, Spiller RC, West J. Concurrent drug use and
the risk of perforated colonic diverticular disease: A population-based
case-control study. Gut. 2011;60(2):219–24.
120. Lanas A, García-Rodríguez LA, Arroyo MT, Gomollón F, Feu F, Gon-
zález-Pérez A, et al. Risk of upper gastrointestinal ulcer bleeding
associated with selective cyclo-oxygenase-2 inhibitors, traditional
non-aspirin non-steroidal anti-inflammatory drugs, aspirin and com-
binations. Gut. 2006;55(12):1731–8.
121. Lanas A, Carrera-Lasfuentes P, Arguedas Y, García S, Bujanda L,
Calvet X, et al.. Risk of upper and lower gastrointestinal bleeding in
patients taking nonsteroidal anti-inflammatory drugs, antiplatelet
agents, or anticoagulants. Clin Gastroenterol Hepatol.
2015;13(5):906–12.
122. Laporte J, Ibañez L, Vidal X, Vendrell L, Leone R. Upper Gas-
trointestinal Bleeding Associated with the Use of NSAIDs. Drug Saf.
2004;27(6):411–20.
123. Lin CC, Hu HY, Luo JC, Peng YL, Hou MC, Lin HC, et al.. Risk factors
of gastrointestinal bleeding in clopidogrel users: A nationwide po-
pulation-based study. Aliment Pharmacol Ther. 2013;38(9):1119–
28. Cyclo-oxygenase-2 inhibitors or conventional non-steroidal
anti-inflammatory drugs. Bmj. 2002;325(September):624–30.
125. Marra CA, Lynd LD, Colley L, Harvard SS, Lacaille D, Schwenger E,
et al.. Risk of gastrointestinal events in patients with rheumatoid
arthritis after withdrawal of rofecoxib. J Rheumatol.
2012;39(5):910–5.
126. Nagata N, Niikura R, Aoki T, Shimbo T, Kishida Y, Sekine K, et al..
Lower GI bleeding risk of nonsteroidal anti-inflammatory drugs and
antiplatelet drug use alone and the effect of combined therapy. Gas-
trointest Endosc. 2014;80(6):1124–31.
127. Nagata N, Niikura R, Aoki T, Shimbo T, Kishida Y, Sekine K, et al..
Colonic diverticular hemorrhage associated with the use of nonste-
roidal anti-inflammatory drugs, low-dose aspirin, antiplatelet drugs,
and dual therapy. J Gastroenterol Hepatol. 2014;29(10):1786–
93.
128. Norgard B, Pedersen L, Johnsen SP, Tarone RE, McLaughlin JK, Friis